Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA gives Baxter two years to remove infusion pumps from market

This article was originally published in The Silver Sheet

Executive Summary

Baxter has until July 14, 2012, to ensure that all Colleague infusion pumps on the U.S. market have been recalled and destroyed, and that customers have received a refund or a replacement pump, according to a final recall order from FDA. The mandatory recall was announced in May, but FDA and the firm released details of the refund and replacement program July 13. Baxter is removing as many as 200,000 infusion pumps from the domestic market, including about 50,000 triple-channel pumps and 150,000 single-channel pumps. The relatively rare FDA enforcement action stems from a June 2006 consent decree related to persistent safety problems with the devices ("The Silver Sheet" July 2006). Within the next two years, Baxter must replace Colleague infusion pumps with Sigma Spectrum pumps at no cost, or refund customers the lesser of the Colleague pump's depreciated value or the purchase price, according to the July 13 recall order

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts